Be The Match BioTherapies® Launches Bioinformatics Consulting Services

New service providing real-world, data-driven insights in cell and gene therapy to guide the development of safe and effective allogeneic therapies.

Be The Match BioTherapies^®, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced its new Bioinformatics Consulting Services, which blends the unique expertise, real-world data and assets of Be The Match BioTherapies and the CIBMTR^® (Center for International Blood and Marrow Transplant Research^®). By combining the organization’s 30+ year partnerships with researchers, transplant centers, and donors with specially developed modeling software, Be The Match BioTherapies aims to provide developers with insights that impact patient care and provide life-saving treatments.

“Today, with our launch of the Bioinformatics Consulting Services, everyone from cell and gene therapy research and development teams to transplant physicians can access and use our world-class information and expertise to make knowledge-based decisions regarding the potential clinical safety and efficacy of allogeneic cell therapies and uncover actionable ways to put research into practice,” said Dr. Steven Devine, Chief Medical Officer, Be The Match BioTherapies. “Our Bioinformatics Consulting Services operate at the intersection of science and technology, and bridges the transition from cell culture to the clinic.”

The new Bioinformatics Consulting Services help companies mitigate risk by using data-driven answers to make decisions that maximize clinical success and speed allogeneic therapies to market. Its team leverages software tools and analytical methods to facilitate data exchange, interpret information, understand patterns and predict factors to save and improve lives. It is the only organization of its kind to deliver:

• Modeling and Match Projection: Access the most diverse repository of HLA data collected from healthy adult volunteer donors and umbilical cord blood.
• Histocompatibility and Genotype Interpretation: Population Haplotype Frequencies - Estimated for U.S. and world populations from HLA data collected from millions of volunteer donors.
• Population Genetics: Over 30 years of hematopoietic cell transplantation (HCT) and cellular therapies patient outcomes data.
• Population-level Imputation: Unique experience in HLA and KIR genotype interpretation and factors of donor/recipient histocompatibility for cellular therapy success.

The Bioinformatics Consulting Services experts include Martin Maiers, Vice President, Research; Abeer Madbouly, Principal Bioinformatics Scientist; Michael Wright, Scientific Coordinator; Heather Stefanski, MD, PhD, Vice President, Medical Services; and Steve Devine, MD, Chief Medical Officer.

About Be The Match BioTherapies

Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program^®/Be The Match^® and a research partnership with the CIBMTR^® (Center for International Blood and Marrow Transplant Research^®), the organization designs solutions that advance the development of cell and gene therapies across the globe.

Be The Match BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the Be The Match Registry^®, the world’s most diverse registry of more than 7 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection, and transplant centers worldwide, the organization develops, onboards, trains, and manages expansive collection networks to advance cell therapies. Be The Match BioTherapies uses a proven infrastructure consisting of regulatory compliance and managed logistics experts and cell therapy supply chain case managers to successfully transport and deliver regulatory-compliant life-saving therapies across the globe. Through the CIBMTR, Be The Match BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for FDA-approved CAR-T therapies.

For more information, visit www.BeTheMatchBioTherapies.com or follow Be The Match BioTherapies on LinkedIn or Twitter.

About the CIBMTR

The CIBMTR^® (Center for International Blood and Marrow Transplant Research^®) is a research collaboration between the National Marrow Donor Program^® (NMDP)/Be The Match^® and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a network of more than 300 transplant centers, and one of the largest databases worldwide for clinical outcomes of cellular therapy, and a biorepository with tissue samples.

For more information on the CIBMTR, please visit www.cibmtr.org or follow the CIBMTR on Facebook, LinkedIn or Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005413/en/